Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +6.62%8 Return-on-Tangible-Asset is -20.89% as of Dec. 2025. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, Alamar Biosciences ranks worse than 72.51% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Alamar Biosciences's annualizedNet Income for the quarter that ended in Dec. 2025 was $-29.82 Mil. Alamar Biosciences's average total tangible assets for the quarter that ended in Dec. 2025 was $142.74 Mil. Therefore, Alamar Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -20.89%.
The historical rank and industry rank for Alamar Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
ALMR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -31.92 Med: -26.41 Max: -20.89
Current: -20.89
During the past 2 years, Alamar Biosciences's highest Return-on-Tangible-Asset was -20.89%. The lowest was -31.92%. And the median was -26.41%.
ALMR's Return-on-Tangible-Asset is ranked worse than 72.51% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs ALMR: -20.89
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Alamar Biosciences Return-on-Tangible-Asset Related Terms
Alamar Biosciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Return-on-Tangible-Asset Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Return-on-Tangible-Asset
-31.92
-20.89
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
Return-on-Tangible-Asset
-31.92
-20.89
ALMR vs UFPT, BFLY, ENOV: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Alamar Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -20.89% mean?
Alamar Biosciences (ALMR) has a Return-on-Tangible-Asset of -20.89% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alamar Biosciences and its competitors. According to the industry distribution chart, Alamar Biosciences ranks #620 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 72.5%.
Is Alamar Biosciences' Return-on-Tangible-Asset too high?
Alamar Biosciences' current Return-on-Tangible-Asset is -20.89%. Based on the distribution chart, Alamar Biosciences ranks #620 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Return-on-Tangible-Asset compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #620 out of 855 companies for Return-on-Tangible-Asset. This places Alamar Biosciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.56, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Return-on-Tangible-Asset is -20.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Return-on-Tangible-Asset of -20.89%. The current Return-on-Tangible-Asset is -20.89%. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Return-on-Tangible-Asset is -20.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
